Evotec SE – NASDAQ:EVO
Evotec SE stock price today
$3.64
-0.89
-19.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Evotec SE stock price monthly change
-8.10%
month
Evotec SE stock price quarterly change
-8.10%
quarter
Evotec SE stock price yearly change
-61.82%
year
Evotec SE key metrics
Market Cap | 1.54B |
Enterprise value | 3.70B |
P/E | -17.64 |
EV/Sales | 5.31 |
EV/EBITDA | -26.40 |
Price/Sales | 4.48 |
Price/Book | 2.54 |
PEG ratio | N/A |
EPS | -0.51 |
Revenue | 776.59M |
EBITDA | -74.54M |
Income | -90.68M |
Revenue Q/Q | -2.26% |
Revenue Y/Y | -2.96% |
Profit margin | -25.78% |
Oper. margin | -0.27% |
Gross margin | 20.59% |
EBIT margin | -0.27% |
EBITDA margin | -9.6% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEvotec SE stock price history
Evotec SE stock forecast
Evotec SE financial statements
| Jun 2023 | 170.27M | -14.92M | -8.77% |
|---|---|---|---|
| Sep 2023 | 196.27M | -38.95M | -19.85% |
| Dec 2023 | 201.31M | -16.13M | -8.01% |
| Mar 2024 | 208.72M | -20.67M | -9.9% |
| Dec 2023 | 201.31M | -16.13M | -8.01% |
|---|---|---|---|
| Mar 2024 | 208.72M | -20.67M | -9.9% |
| Sep 2025 | 289.15M | 7.85M | 2.72% |
| Dec 2025 | 308.66M | 8.72M | 2.83% |
Analysts Price target
Financials & Ratios estimates
| 2022-08-11 | -0.38014 | -0.08 |
|---|---|---|
| 2022-11-09 | 0.08 | -0.13377 |
| 2023-03-29 | -0.42406 | -0.13 |
| 2023-05-12 | 0.1 | -0.08 |
| Jun 2023 | 2301221000 | 1.12B | 48.97% |
|---|---|---|---|
| Sep 2023 | 2254509000 | 1.11B | 49.4% |
| Dec 2023 | 2299053000 | 1.17B | 51.29% |
| Mar 2024 | 2208650000 | 1.10B | 49.9% |
| Jun 2023 | -6.20M | 33.44M | 13.95M |
|---|---|---|---|
| Sep 2023 | 20.75M | -15.76M | 43.36M |
| Dec 2023 | 18.76M | -36.68M | 30.96M |
| Mar 2024 | -47.19M | -31.97M | -5.78M |
Evotec SE alternative data
| Aug 2023 | 4,952 |
|---|---|
| Sep 2023 | 5,067 |
| Oct 2023 | 5,067 |
| Nov 2023 | 5,067 |
| Dec 2023 | 5,086 |
| Jan 2024 | 5,086 |
| Feb 2024 | 5,086 |
| Mar 2024 | 5,086 |
| Apr 2024 | 5,086 |
| May 2024 | 5,061 |
| Jun 2024 | 5,055 |
| Jul 2024 | 5,055 |
Evotec SE other data
0.58%
-0.98%
of EVO is owned by hedge funds
1.02M
-1.57M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 22 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 24 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q1 2023 22 Jan 2024 | Q1 2023 Earnings Call Transcript |
| Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
Halozyme: Recent Approvals Alter My Appetite
Evotec: Some Recovery Has Come, But Much More Is Expected
Evotec: Still A Speculative Buy After A Significant Decline
Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better
Evotec: Significantly Undervalued, Or Value Trap?
Revisiting My Summer Quant Analysis, Plus Literature Insights
Evotec SE: Profitable, Innovative, And The Omics Opportunity
-
What's the price of Evotec SE stock today?
One share of Evotec SE stock can currently be purchased for approximately $3.64.
-
When is Evotec SE's next earnings date?
Unfortunately, Evotec SE's (EVO) next earnings date is currently unknown.
-
Does Evotec SE pay dividends?
No, Evotec SE does not pay dividends.
-
How much money does Evotec SE make?
Evotec SE has a market capitalization of 1.54B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.99% to 781.43M US dollars. Evotec SE made a loss 83.91M US dollars in net income (profit) last year or -$0.08 on an earnings per share basis.
-
What is Evotec SE's stock symbol?
Evotec SE is traded on the NASDAQ under the ticker symbol "EVO".
-
What is Evotec SE's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Evotec SE?
Shares of Evotec SE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Evotec SE have?
As Jul 2024, Evotec SE employs 5,055 workers, which is 1% less then previous quarter.
-
When Evotec SE went public?
Evotec SE is publicly traded company for more then 21 years since IPO on 5 Feb 2004.
-
What is Evotec SE's official website?
The official website for Evotec SE is evotec.com.
-
How can i contact Evotec SE?
Evotec SE can be reached via phone at +49 40 560810.
Evotec SE company profile:
Evotec SE
evotec.comExchange:
NASDAQ
Full time employees:
5,007
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Essener Bogen 7
Hamburg, 22419
Hamburg, 22419
CIK: 0001412558
ISIN: US30050E1055
CUSIP: 30050E105
